Abstract
Melanoma is a malignant tumor that can rapidly develop resistance to treatment because of its high mutational activity. The introduction of tyrosine kinase receptor inhibitors (BRAF, MEK) and cytotoxic T lymphocyte antigen/receptor inhibitors (CTLA4, PD-1) into clinical practice has led to an increase in patient survival rates. In in vitro studies, combining PIK3 and MEK inhibitors demonstrate a pronounced reduction in tumor cell growth. The phenomenon of synthetic lethality is also promising, allowing the high mutational load of melanoma to be used as a tool for the development of more effective drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
